HRP20100563T1 - Derivati dihidropirazolopirimidinona - Google Patents

Derivati dihidropirazolopirimidinona Download PDF

Info

Publication number
HRP20100563T1
HRP20100563T1 HR20100563T HRP20100563T HRP20100563T1 HR P20100563 T1 HRP20100563 T1 HR P20100563T1 HR 20100563 T HR20100563 T HR 20100563T HR P20100563 T HRP20100563 T HR P20100563T HR P20100563 T1 HRP20100563 T1 HR P20100563T1
Authority
HR
Croatia
Prior art keywords
group
phenyl
dihydro
amino
salt
Prior art date
Application number
HR20100563T
Other languages
English (en)
Croatian (hr)
Inventor
Sakamoto Toshihiro
Sunami Satoshi
Yamamoto Fuyuki
Niiyama Kenji
Bamba Makoto
Takahashi Keiji
Furuyama Hidetomo
Sagara Takeshi
Otsuki Sachie
Nishibata Toshihide
Yoshizumi Takashi
Hirai Hiroshi
Original Assignee
Banyu Pharmaceutical Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38655640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100563(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Banyu Pharmaceutical Co. filed Critical Banyu Pharmaceutical Co.
Publication of HRP20100563T1 publication Critical patent/HRP20100563T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20100563T 2006-04-27 2007-04-25 Derivati dihidropirazolopirimidinona HRP20100563T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006124208 2006-04-27
PCT/JP2007/059408 WO2007126122A1 (en) 2006-04-27 2007-04-25 Dihydropyrazolopyrimidinone derivatives

Publications (1)

Publication Number Publication Date
HRP20100563T1 true HRP20100563T1 (hr) 2010-11-30

Family

ID=38655640

Family Applications (2)

Application Number Title Priority Date Filing Date
HR20100563T HRP20100563T1 (hr) 2006-04-27 2007-04-25 Derivati dihidropirazolopirimidinona
HRP20161763TT HRP20161763T1 (hr) 2006-04-27 2007-04-25 Derivati dihidropirazolopirimidinona

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20161763TT HRP20161763T1 (hr) 2006-04-27 2007-04-25 Derivati dihidropirazolopirimidinona

Country Status (38)

Country Link
US (4) US7834019B2 (lt)
EP (2) EP2017278B1 (lt)
JP (2) JP4513919B2 (lt)
KR (1) KR101409161B1 (lt)
CN (1) CN101432284B (lt)
AR (1) AR060635A1 (lt)
AT (1) ATE475662T1 (lt)
AU (1) AU2007244185B2 (lt)
BR (1) BRPI0710081A2 (lt)
CA (1) CA2650119C (lt)
CR (1) CR10359A (lt)
CY (2) CY1111069T1 (lt)
DE (1) DE602007008085D1 (lt)
DK (2) DK2016080T3 (lt)
DO (1) DOP2007000084A (lt)
EC (1) ECSP088812A (lt)
ES (2) ES2348751T3 (lt)
GT (1) GT200800211A (lt)
HN (1) HN2008001532A (lt)
HR (2) HRP20100563T1 (lt)
HU (1) HUE032987T2 (lt)
IL (1) IL194367A (lt)
LT (1) LT2017278T (lt)
MA (1) MA30428B1 (lt)
MX (1) MX2008013063A (lt)
MY (1) MY145408A (lt)
NO (1) NO341617B1 (lt)
NZ (1) NZ571196A (lt)
PE (1) PE20080695A1 (lt)
PL (2) PL2016080T3 (lt)
PT (2) PT2017278T (lt)
RU (1) RU2437885C2 (lt)
SI (2) SI2016080T1 (lt)
SV (1) SV2009003060A (lt)
TW (1) TWI409262B (lt)
UA (1) UA96152C2 (lt)
WO (2) WO2007126122A1 (lt)
ZA (1) ZA200807748B (lt)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
JP5411847B2 (ja) * 2007-04-25 2014-02-12 Ｍｓｄ株式会社 Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形
WO2008141385A1 (en) * 2007-05-21 2008-11-27 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
WO2009054332A1 (ja) * 2007-10-23 2009-04-30 Banyu Pharmaceutical Co., Ltd. ピリドン置換ジヒドロピラゾロピリミジノン誘導体
WO2009151997A1 (en) * 2008-06-12 2009-12-17 Merck & Co., Inc. Process for producing bicycloaniline derivatives
AU2009325400A1 (en) * 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivatives
WO2010076887A1 (en) * 2009-01-05 2010-07-08 Banyu Pharmaceutical Co.,Ltd. Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
AU2010218781A1 (en) * 2009-02-25 2011-07-28 Msd K.K. Pyrimidopyrimidoindazole derivative
US20120157342A1 (en) * 2009-09-02 2012-06-21 Shinji Mizuarai Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
EP2477628B1 (en) 2009-09-15 2014-08-20 Merck Sharp & Dohme Corp. Preparation of crystalline hemihydrate forms of dihydropyrazolopyrimidinone
RU2017127088A (ru) 2010-11-16 2019-02-04 Эррэй Биофарма Инк. Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1
CN103492363B (zh) * 2011-04-27 2016-08-24 日本瑞翁株式会社 聚合性化合物、聚合性组合物、高分子以及光学各向异性体
US8796289B2 (en) 2011-07-19 2014-08-05 Abbvie Inc. Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
WO2013039854A1 (en) 2011-09-15 2013-03-21 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
US9181239B2 (en) 2011-10-20 2015-11-10 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
MX2014010176A (es) * 2012-02-23 2014-11-10 Abbvie Inc Inhibidores de cinasas de piridopirimidinona.
WO2014062454A1 (en) * 2012-10-15 2014-04-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
EP2983661B1 (en) 2013-04-09 2024-05-29 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
KR102032933B1 (ko) * 2014-12-17 2019-10-16 데루타-후라이 화마 가부시키가이샤 고령이나 말기의 암환자를 치료 또는 경감하기 위한 의약 조성물
US20160304496A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
AR104291A1 (es) 2015-04-17 2017-07-12 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
US9879016B2 (en) 2015-04-17 2018-01-30 Abbvie Inc. Indazolones as modulators of TNF signaling
JP6141568B1 (ja) * 2015-09-01 2017-06-07 大鵬薬品工業株式会社 新規なピラゾロ［３，４−ｄ］ピリミジン化合物又はその塩
CN105130986B (zh) * 2015-09-30 2017-07-18 广州科擎新药开发有限公司 嘧啶或吡啶并吡啶酮类化合物及其应用
JP6692423B2 (ja) * 2015-11-01 2020-05-13 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト Ｗｅｅ１キナーゼ阻害剤、並びにそれを作製及び使用する方法
GB201612092D0 (en) 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
AU2017327539B2 (en) 2016-09-15 2020-12-24 Boehringer Ingelheim International Gmbh Heteroaryl carboxamide compounds as inhibitors of RIPK2
CN106719769A (zh) * 2016-11-28 2017-05-31 山东农业大学 一种含香菇多糖、苯醚甲环唑和噻虫啉的病虫兼治农药组合物
MX2019006694A (es) 2016-12-08 2019-08-21 Lixte Biotechnology Inc Oxabicicloheptanos para la modulacion de la respuesta inmunitaria.
JP6717457B2 (ja) * 2017-01-23 2020-07-01 シージャーズォアン サガシティ ニュー ドラッグ デベロップメント カンパニー リミテッド Ｗｅｅ１阻害剤としての１，２−ジヒドロ−３Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−３−オン誘導体
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
US11248006B2 (en) 2017-03-23 2022-02-15 Shanghai De Novo Pharmatech Co., Ltd. Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof
CN110678169A (zh) 2017-03-31 2020-01-10 西雅图遗传学公司 Chk1-抑制剂与weel-抑制剂的组合
MX2020001235A (es) 2017-08-01 2020-07-20 Recurium Ip Holdings Llc Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
EP3694861A4 (en) * 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
AU2018347307A1 (en) 2017-10-09 2020-04-23 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
SG11202003974XA (en) 2017-11-01 2020-05-28 Shijiazhuang Sagacity New Drug Development Co Ltd Macrocyclic compound serving as weel inhibitor and applications thereof
CN109810111B (zh) * 2017-11-20 2023-10-27 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
WO2019134539A1 (zh) * 2018-01-05 2019-07-11 四川科伦博泰生物医药股份有限公司 二氢吡唑酮并嘧啶类化合物及其制备方法和用途
WO2019165204A1 (en) * 2018-02-23 2019-08-29 Newave Pharmaceutical Inc. 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidine-3-one compounds as inhibitors of wee-1 kinase
US12220415B2 (en) 2018-02-28 2025-02-11 The Regents Of The University Of Colorado, A Body Corporate WEE1 kinase inhibitors and methods of treating cancer using the same
EP4566612A3 (en) 2018-03-09 2025-08-20 Recurium IP Holdings, LLC Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
CN108653282B (zh) * 2018-06-28 2020-08-14 中国科学院昆明植物研究所 苯并噻唑类及苯并吡咯类化合物在制备抗肿瘤药物中的应用
US12180184B2 (en) 2018-10-26 2024-12-31 Wuxi Biocity Biopharmaceutics Co., Ltd. Pyrimidopyrazolone derivative as Wee1 inhibitor and use thereof
CN113480541B (zh) * 2019-03-07 2022-09-02 湖南化工研究院有限公司 咪唑并吡啶化合物及其中间体的制备方法
KR102697799B1 (ko) * 2019-03-22 2024-08-23 쇼우야오 홀딩스 (베이징) 코., 엘티디. Wee1 억제제 및 이의 제조 및 용도
US20220220115A1 (en) * 2019-04-09 2022-07-14 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
JP2022526831A (ja) 2019-04-09 2022-05-26 ニューベイション・バイオ・インコーポレイテッド ヘテロ環式化合物およびその使用
WO2020210320A1 (en) * 2019-04-11 2020-10-15 Recurium Ip Holdings, Llc Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
SI3964510T1 (sl) 2019-04-30 2024-10-30 Wuxi Biocity Biopharmaceutics Co., Ltd. Kristalna oblika WEE1 inhibitorske spojine in njena uporaba
CN112142748B (zh) 2019-06-28 2023-07-04 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
BR112021026618A2 (pt) 2019-06-28 2022-06-07 Shanghai Pharmaceuticals Holding Co Ltd Composto de pirazolpirimidina, método de preparação do mesmo e aplicações do mesmo
EP4048277A1 (en) 2019-10-25 2022-08-31 Astrazeneca AB Methods of treating cancer
JP2023507797A (ja) * 2019-12-20 2023-02-27 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 組み合わせ
CN113387962A (zh) * 2020-03-12 2021-09-14 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
CA3180664A1 (en) 2020-06-17 2021-12-23 Yuli Xie Pyrazolo[3,4-d]pyrimidine-3-one derivative as wee-1 inhibitor
US12551584B1 (en) 2020-12-07 2026-02-17 Actinium Pharmaceuticals, Inc. Lewis Y radioimmunotherapy for the treatment of cancer
KR102549484B1 (ko) * 2020-12-08 2023-06-29 한국화학연구원 피라졸로피리미딘 설폰아마이드 유도체 및 이를 유효성분으로 포함하는 암 관련 질환의 예방 또는 치료용 약학적 조성물
WO2022171088A1 (zh) * 2021-02-09 2022-08-18 微境生物医药科技(上海)有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物
WO2022171126A1 (zh) * 2021-02-09 2022-08-18 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的稠环化合物
CN116848118A (zh) * 2021-02-09 2023-10-03 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的吡唑并[3,4-d]嘧啶-3-酮衍生物
CN115197221B (zh) * 2021-04-02 2024-05-24 轩竹(北京)医药科技有限公司 二氢吡唑并嘧啶酮类大环衍生物及其用途
KR20240004584A (ko) 2021-04-29 2024-01-11 노파르티스 아게 탈유비퀴티나아제-표적화 키메라 및 관련된 방법
KR20240004539A (ko) 2021-04-30 2024-01-11 위겐 바이오메더슨 테크널러지 (상하이) 컴퍼니 리미티드 Wee-1 억제제로서의 축합 고리 화합물, 그를 위한 제조 방법 및 그의 용도
EP4349838A4 (en) 2021-05-28 2025-08-13 Jiangsu Tasly Diyi Pharmaceutical Co Ltd WEE1 INHIBITOR AND ITS USE
CN117794932A (zh) * 2021-06-04 2024-03-29 阿普里治疗股份有限公司 可用作wee1激酶抑制剂的吡啶并嘧啶衍生物
TW202328142A (zh) * 2021-09-18 2023-07-16 香港商優領醫藥科技(香港)有限公司 含嘧啶并二氫吡唑啉酮類衍生物、其藥學上可接受的鹽及其製備方法和應用
CN113880844B (zh) * 2021-09-29 2023-02-14 武汉九州钰民医药科技有限公司 Wee1蛋白激酶抑制剂adavosertib的化学合成方法
CN113735863A (zh) * 2021-09-29 2021-12-03 武汉九州钰民医药科技有限公司 Wee1抑制剂adavosertib的制备工艺
WO2023072301A1 (zh) * 2021-11-01 2023-05-04 正大天晴药业集团股份有限公司 吡唑[3,4-d]嘧啶-3-酮类化合物及其医药用途
CN116462687B (zh) 2022-01-18 2025-01-07 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
CN116836184B (zh) * 2022-03-25 2025-07-25 药雅科技(上海)有限公司 Wee1激酶抑制剂的制备及其应用
CN115073460B (zh) * 2022-07-13 2023-07-25 苏州施安鼎泰生物医药技术有限公司 一种嘧啶并[5,4-c][2,6]萘啶衍生物及其制备方法以及药物组合物和应用
CN117402162A (zh) 2022-07-13 2024-01-16 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
WO2024012549A1 (zh) * 2022-07-15 2024-01-18 映恩生物制药（苏州）有限公司 一种嘧啶并五元杂环化合物、其制备方法和用途
CN119798282A (zh) * 2023-10-11 2025-04-11 智擎生技制药股份有限公司 基于稠合吡啶环的Myt1抑制剂
TW202519226A (zh) 2023-11-08 2025-05-16 美商艾克塞里克斯公司 使用抑制ｐｋｍｙｔ１之化合物治療癌症之方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA07174A (fr) 1981-08-24 1984-04-30 May & Baker Ltd Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent.
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP2628707B2 (ja) * 1987-08-26 1997-07-09 三井製薬工業株式会社 ピリミジン類及びその薬学的に許容される塩類
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
FI931384A7 (fi) 1990-09-28 1993-03-26 Smithkline Beecham Corp Vesiliukoisia kamptotekiinianalogeja, prosesseja ja menetelmiä
US5247089A (en) 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5243050A (en) 1990-12-20 1993-09-07 North Carolina State University Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5191082A (en) 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
US5200524A (en) 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
AU687727B2 (en) 1992-10-28 1998-03-05 Genentech Inc. Vascular endothelial cell growth factor antagonists
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
SE0103649D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
WO2003091255A1 (en) 2002-04-26 2003-11-06 Warner-Lambert Company Llc Inhibitors of checkpoint kinases (wee1 and chk1)
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA05007503A (es) * 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
JP2006518381A (ja) * 2003-02-07 2006-08-10 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なヘテロアリール置換ピロール
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US20050250836A1 (en) * 2004-05-03 2005-11-10 Pfizer Inc Inhibitors of checkpoint kinases (Wee1 and Chk1)
WO2006004040A1 (ja) 2004-07-01 2006-01-12 Daiichi Asubio Pharma Co., Ltd. Ｐｄｅ７阻害作用を有するチエノピラゾール誘導体
EP1846408B1 (en) 2005-01-14 2013-03-20 Janssen Pharmaceutica NV 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2006091737A1 (en) * 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
PE20080695A1 (es) * 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel

Also Published As

Publication number Publication date
TW200811176A (en) 2008-03-01
MX2008013063A (es) 2008-12-16
EP2016080B1 (en) 2010-07-28
NZ571196A (en) 2011-03-31
PT2016080E (pt) 2010-10-14
RU2437885C2 (ru) 2011-12-27
US20100063024A1 (en) 2010-03-11
AU2007244185B2 (en) 2012-10-04
CA2650119C (en) 2017-03-14
SV2009003060A (es) 2009-04-28
CR10359A (es) 2009-02-19
PE20080695A1 (es) 2008-06-28
EP2016080A1 (en) 2009-01-21
GT200800211A (es) 2009-04-07
US7935708B2 (en) 2011-05-03
EP2016080A4 (en) 2009-05-13
KR20090017491A (ko) 2009-02-18
EP2017278A1 (en) 2009-01-21
HK1132498A1 (en) 2010-02-26
CN101432284A (zh) 2009-05-13
ES2609087T3 (es) 2017-04-18
DK2017278T3 (en) 2017-02-13
DOP2007000084A (es) 2007-12-31
PT2017278T (pt) 2017-01-03
EP2017278A4 (en) 2009-04-22
HN2008001532A (es) 2009-06-10
JP4513919B2 (ja) 2010-07-28
JP5167291B2 (ja) 2013-03-21
HUE032987T2 (en) 2017-11-28
ECSP088812A (es) 2008-11-27
ATE475662T1 (de) 2010-08-15
US7834019B2 (en) 2010-11-16
CY1111069T1 (el) 2012-05-23
NO341617B1 (no) 2017-12-11
NO20084968L (no) 2008-11-26
US20110189130A1 (en) 2011-08-04
CN101432284B (zh) 2012-08-15
IL194367A (en) 2014-12-31
DK2016080T3 (da) 2010-11-22
CY1118526T1 (el) 2017-07-12
US8791125B2 (en) 2014-07-29
IL194367A0 (en) 2009-08-03
PL2017278T3 (pl) 2017-10-31
WO2007126128A1 (ja) 2007-11-08
BRPI0710081A2 (pt) 2011-08-02
ES2348751T3 (es) 2010-12-13
HRP20161763T1 (hr) 2017-02-24
US20140303178A1 (en) 2014-10-09
SI2017278T1 (sl) 2017-05-31
AU2007244185A1 (en) 2007-11-08
PL2016080T3 (pl) 2011-03-31
MA30428B1 (fr) 2009-05-04
RU2008146759A (ru) 2010-06-10
SI2016080T1 (sl) 2011-03-31
JP2010132689A (ja) 2010-06-17
MY145408A (en) 2012-02-15
UA96152C2 (en) 2011-10-10
KR101409161B1 (ko) 2014-06-19
CA2650119A1 (en) 2007-11-08
JPWO2007126128A1 (ja) 2009-09-17
AR060635A1 (es) 2008-07-02
TWI409262B (zh) 2013-09-21
ZA200807748B (en) 2009-10-28
DE602007008085D1 (en) 2010-09-09
EP2017278B1 (en) 2016-11-02
US20070254892A1 (en) 2007-11-01
WO2007126122A1 (en) 2007-11-08
LT2017278T (lt) 2017-01-25

Similar Documents

Publication Publication Date Title
HRP20100563T1 (hr) Derivati dihidropirazolopirimidinona
HRP20161536T1 (hr) Derivat bicikloanilina
EP2213673B1 (en) Pyridone-substituted-dihydropyrazolopyrimidinone derivative
ES2580779T3 (es) Pirimidinas fusionadas
AU2009279944B2 (en) Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
EP2376493B1 (en) Dihydropyrimidopyrimidine derivative
EP2155752B1 (en) Polymorph of dihydropyrazolopyrimidinone derivative as weel kinase.inhibitor
IL292229A (en) Pharmacological combination of prmt5 inhibitors
ES2435804T3 (es) Pirimidinas condensadas como inhibidores de Akt
JP2012518598A5 (lt)
JP2010525057A5 (lt)
AU2008288392B2 (en) Fused bicyclic pyrimidines
RU2009111599A (ru) Новые аминопиридиновые производные с селективной ингибирующей активностью в отношении авроры а
CA2745959A1 (en) Dihydropyrimidopyrimidine derivatives
AU2023342153A1 (en) Brm targeting compounds and associated methods of use
RU2007119776A (ru) Новые аминопиридиновые производные, обладающие селективной aurora a ингибирующей активностью
EP2651949B1 (en) Substituted pyrimido[1,2-b]indazoles and their use as modulators of the pi3k/akt pathway
WO2025184459A1 (en) Brm and brg1 targeting compounds and associated methods of use
HK1166984B (en) Fused pyrimidines as akt inhibitors